DK3585891T3 - Fremgangsmåder til oprensning af messenger-rna - Google Patents

Fremgangsmåder til oprensning af messenger-rna Download PDF

Info

Publication number
DK3585891T3
DK3585891T3 DK18711201.6T DK18711201T DK3585891T3 DK 3585891 T3 DK3585891 T3 DK 3585891T3 DK 18711201 T DK18711201 T DK 18711201T DK 3585891 T3 DK3585891 T3 DK 3585891T3
Authority
DK
Denmark
Prior art keywords
purification
methods
messenger rna
messenger
rna
Prior art date
Application number
DK18711201.6T
Other languages
English (en)
Inventor
Jonathan Abysalh
Daniel Crawford
Frank Derosa
Shrirang Karve
Anusha Dias
Michael Heartlein
Original Assignee
Translate Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translate Bio Inc filed Critical Translate Bio Inc
Application granted granted Critical
Publication of DK3585891T3 publication Critical patent/DK3585891T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1017Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502753Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/02Adapting objects or devices to another
    • B01L2200/028Modular arrangements
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/16Reagents, handling or storing thereof
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/06Auxiliary integrated devices, integrated components
    • B01L2300/0681Filter
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00Moving or stopping fluids
    • B01L2400/04Moving fluids with specific forces or mechanical means
    • B01L2400/0403Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0409Moving fluids with specific forces or mechanical means specific forces centrifugal forces
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2523/00Reactions characterised by treatment of reaction samples
    • C12Q2523/10Characterised by chemical treatment
    • C12Q2523/113Denaturating agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2523/00Reactions characterised by treatment of reaction samples
    • C12Q2523/30Characterised by physical treatment
    • C12Q2523/308Adsorption or desorption
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y201/00Transferases transferring one-carbon groups (2.1)
    • C12Y201/03Carboxy- and carbamoyltransferases (2.1.3)
    • C12Y201/03003Ornithine carbamoyltransferase (2.1.3.3)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Clinical Laboratory Science (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK18711201.6T 2017-02-27 2018-02-27 Fremgangsmåder til oprensning af messenger-rna DK3585891T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762463998P 2017-02-27 2017-02-27
PCT/US2018/019954 WO2018157133A1 (en) 2017-02-27 2018-02-27 Methods for purification of messenger rna

Publications (1)

Publication Number Publication Date
DK3585891T3 true DK3585891T3 (da) 2021-11-22

Family

ID=61628474

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18711201.6T DK3585891T3 (da) 2017-02-27 2018-02-27 Fremgangsmåder til oprensning af messenger-rna

Country Status (11)

Country Link
US (2) US10808241B2 (da)
EP (2) EP3971291A1 (da)
AU (1) AU2018224843A1 (da)
CA (1) CA3054321A1 (da)
CY (1) CY1124735T1 (da)
DK (1) DK3585891T3 (da)
ES (1) ES2899323T3 (da)
HU (1) HUE059025T2 (da)
IL (1) IL268857B1 (da)
MA (1) MA47605A (da)
WO (1) WO2018157133A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2838063C (en) 2011-06-08 2023-07-11 Shire Human Genetic Therapies, Inc. Cleavable lipids
WO2014152966A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Methods for purification of messenger rna
WO2018157133A1 (en) * 2017-02-27 2018-08-30 Translate Bio, Inc. Methods for purification of messenger rna
MA50803A (fr) 2017-11-22 2020-09-30 Modernatx Inc Polynucléotides codant pour l'ornithine transcarbamylase pour le traitement de troubles du cycle de l'urée
US20210220449A1 (en) * 2018-05-15 2021-07-22 Translate Bio, Inc. Subcutaneous Delivery of Messenger RNA
CN112930396B (zh) 2018-08-24 2024-05-24 川斯勒佰尔公司 用于纯化信使rna的方法
US20210388338A1 (en) * 2018-11-08 2021-12-16 Translate Bio, Inc. Methods and Compositions for Messenger RNA Purification
BR112021014966A2 (pt) 2019-02-11 2021-10-05 Ethris Gmbh Métodos para purificar moléculas de mrna e para produzir uma composição farmacêutica
MX2021013954A (es) * 2019-05-15 2022-03-11 Translate Bio Inc Métodos de purificación de arn mensajero.
CA3162368A1 (en) 2019-12-20 2021-06-24 Shrirang KARVE Rectal delivery of messenger rna
CN115461042A (zh) 2019-12-20 2022-12-09 翻译生物公司 制备负载mrna的脂质纳米颗粒的改进方法
WO2021163134A1 (en) 2020-02-10 2021-08-19 Translate Bio, Inc. Methods and compositions for messenger rna purification
EP4110296A1 (en) 2020-02-25 2023-01-04 Translate Bio, Inc. Improved processes of preparing mrna-loaded lipid nanoparticles
WO2021226463A1 (en) 2020-05-07 2021-11-11 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
WO2021226436A1 (en) 2020-05-07 2021-11-11 Translate Bio, Inc. Optimized nucleotide sequences encoding sars-cov-2 antigens
AU2021273502A1 (en) 2020-05-15 2023-02-02 Translate Bio, Inc. Lipid nanoparticle formulations for mRNA delivery
JP2023544167A (ja) * 2020-10-01 2023-10-20 トランスレイト バイオ, インコーポレイテッド メッセンジャーrnaの精製のための方法
CN116546976A (zh) 2020-10-06 2023-08-04 翻译生物公司 脂质纳米颗粒的改进工艺和配制
WO2022081548A1 (en) 2020-10-12 2022-04-21 Translate Bio, Inc. Improved process of preparing ice-based lipid nanoparticles
KR20230087536A (ko) 2020-10-12 2023-06-16 트랜슬레이트 바이오 인코포레이티드 Mrna-로딩된 지질 나노입자를 제조하는 개선된 프로세스
EP4313115A1 (en) 2021-03-25 2024-02-07 Translate Bio, Inc. Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
WO2022225918A1 (en) 2021-04-19 2022-10-27 Translate Bio, Inc. Improved compositions for delivery of mrna
CN117881395A (zh) 2021-07-01 2024-04-12 翻译生物公司 用于递送mRNA的组合物
WO2023086893A1 (en) 2021-11-10 2023-05-19 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024112652A1 (en) 2022-11-21 2024-05-30 Translate Bio, Inc. Compositions of dry powder formulations of messenger rna and methods of use thereof

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5139667A (en) 1988-12-20 1992-08-18 Sparkler Filters, Inc. Nutsche process filter drive unit
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5234809A (en) * 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
US5544425A (en) 1995-05-17 1996-08-13 Mallinckrodt Medical, Inc. Aggressive convective drying in a nutsche type filter/dryer
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
JP3930616B2 (ja) 1997-08-25 2007-06-13 住友化学株式会社 2−アミノ−6置換プリンの精製方法
DE19917558C2 (de) 1999-04-19 2003-05-08 Joachim Schwindling Filtrationsapparat
EP1390414B1 (de) 2001-05-14 2006-08-30 Polytag Technology SA Verfahren zur abtrennung von reversibel thermopräzipitierbaren oligomeren n-substituierter (meth)acrylamidverbindungen und deren konjugate
DE10131107A1 (de) 2001-06-27 2003-01-09 Mann & Hummel Filter Filtervorrichtung bzw. schwenkbares Filtermedium für diese Filtervorrichtung
JP2004167345A (ja) 2002-11-19 2004-06-17 Sumitomo Chem Co Ltd 固体粒子の洗浄方法
US7267950B2 (en) * 2003-05-01 2007-09-11 Veridex, Lcc Rapid extraction of RNA from cells and tissues
JP4663631B2 (ja) 2004-04-28 2011-04-06 天野エンザイム株式会社 放線菌由来のampデアミナーゼ及びその利用
US7473511B2 (en) * 2004-12-15 2009-01-06 Fuji Xerox Co., Ltd. Particle dispersion for electrostatic image-developing toners, electrostatic image-developing toner, and method for producing the same
US7494794B2 (en) 2006-03-31 2009-02-24 Toyo Boseki Kabushiki Kaisha Glucose dehydrogenase
WO2008078646A1 (ja) 2006-12-22 2008-07-03 Ajinomoto Co., Inc. アミノ酸又は核酸の結晶の分離方法
US20090065435A1 (en) 2007-09-10 2009-03-12 Powell Intellectual Property Holdings, Llc Modified Biogenic Silica and Method for Purifying a Liquid
US20090148384A1 (en) 2007-12-10 2009-06-11 Fischer Katrin Functionalized, solid polymer nanoparticles comprising epothilones
NZ588408A (en) 2008-04-16 2012-05-25 Biogen Idec Inc Method of isolating proteins using polyethylene glycol and zinc
MX353900B (es) 2008-11-07 2018-02-01 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
US20130059008A1 (en) * 2009-01-23 2013-03-07 Jeffrey L. Atkinson Drying methods for tuning microparticle properties
US20120165500A1 (en) 2009-08-27 2012-06-28 Newlight Technologies, Llc Process for the production of polyhydroxyalkanoates
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
EP3318248B1 (en) * 2009-12-01 2019-04-10 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
CA2838063C (en) 2011-06-08 2023-07-11 Shire Human Genetic Therapies, Inc. Cleavable lipids
NZ719345A (en) 2011-06-08 2023-03-31 Translate Bio Inc Lipid nanoparticle compositions and methods for mrna delivery
AU2012286901B2 (en) * 2011-07-25 2016-10-27 Sangamo Therapeutics, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
MX363734B (es) 2011-10-27 2019-03-29 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco.
JP6211054B2 (ja) 2012-03-29 2017-10-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 脂質誘導される中性ナノ粒子
JP6283655B2 (ja) 2012-03-29 2018-02-21 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド イオン化可能なカチオン性脂質
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
ES2864878T3 (es) 2012-06-08 2021-10-14 Translate Bio Inc Administración pulmonar de ARN, a células objetivo no pulmonares
ES2968649T3 (es) 2012-12-07 2024-05-13 Translate Bio Inc Nanopartículas lipídicas para la administración de ARNm en los pulmones
WO2014152940A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
WO2014152966A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Methods for purification of messenger rna
AU2014239250A1 (en) 2013-03-14 2015-08-27 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger RNA
JP2016515216A (ja) 2013-03-14 2016-05-26 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド メッセンジャーrnaのキャップ効率の定量的評価
JP6399560B2 (ja) 2013-03-14 2018-10-03 トランスレイト バイオ, インコーポレイテッド mRNAによってコードされる抗体を送達するための方法及び組成物
PL2968586T3 (pl) 2013-03-14 2019-01-31 Translate Bio, Inc. Kompozycje mrna cftr i związne z nimi sposoby i zastosowania
EP3750903A1 (en) 2013-03-14 2020-12-16 Translate Bio, Inc. Ribonucleic acids with 4'-thio-modified nucleotides and related methods
LT2970948T (lt) 2013-03-15 2019-03-25 Glaxosmithkline Biologicals Sa Rna gryninimo būdai
CN112656954A (zh) 2013-10-22 2021-04-16 夏尔人类遗传性治疗公司 用于递送信使rna的脂质制剂
WO2015061500A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for argininosuccinate synthetase deficiency
CN105658242A (zh) 2013-10-22 2016-06-08 夏尔人类遗传性治疗公司 用于苯丙酮尿症的mrna疗法
EP4036241A1 (en) 2013-10-22 2022-08-03 Translate Bio, Inc. Cns delivery of mrna and uses thereof
EP3122878B1 (en) 2014-03-24 2018-10-24 Translate Bio, Inc. Mrna therapy for the treatment of ocular diseases
WO2015164773A1 (en) 2014-04-25 2015-10-29 Shire Human Genetic Therapies, Inc. Methods for purification of messenger rna
WO2015184256A2 (en) 2014-05-30 2015-12-03 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
EP3160959B1 (en) 2014-06-24 2023-08-30 Translate Bio, Inc. Stereochemically enriched compositions for delivery of nucleic acids
EP3164112A1 (en) 2014-07-02 2017-05-10 Shire Human Genetic Therapies, Inc. Encapsulation of messenger rna
EP3900702A1 (en) 2015-03-19 2021-10-27 Translate Bio, Inc. Mrna therapy for pompe disease
KR101693166B1 (ko) 2016-07-12 2017-01-06 정수영 분말 액체 혼합물용 누체 여과 건조 장치
WO2018157133A1 (en) * 2017-02-27 2018-08-30 Translate Bio, Inc. Methods for purification of messenger rna
JP7256824B2 (ja) 2018-04-25 2023-04-12 エスリス ゲーエムベーハー 粒子状製剤用の凍結保護剤

Also Published As

Publication number Publication date
MA47605A (fr) 2020-01-01
EP3585891A1 (en) 2020-01-01
IL268857B1 (en) 2024-05-01
US11976272B2 (en) 2024-05-07
ES2899323T3 (es) 2022-03-10
IL268857A (en) 2019-10-31
US10808241B2 (en) 2020-10-20
AU2018224843A1 (en) 2019-09-19
CA3054321A1 (en) 2018-08-30
US20210123041A1 (en) 2021-04-29
WO2018157133A1 (en) 2018-08-30
CY1124735T1 (el) 2022-07-22
EP3585891B1 (en) 2021-10-27
HUE059025T2 (hu) 2022-10-28
EP3971291A1 (en) 2022-03-23
US20180251755A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
DK3585892T3 (da) Fremgangsmåder til oprensning af messenger-rna
DK3585891T3 (da) Fremgangsmåder til oprensning af messenger-rna
DK3585886T3 (da) Storskalasyntese af messenger-rna
DK4140491T3 (da) Fremgangsmåde til syntetisering af RNA'er med 5'-kappe
DK3445850T3 (da) Fremgangsmåder til tilvejebringelse af enkeltstrenget rna
IL247973A0 (en) Methods for purifying messenger RNA
DK3467108T3 (da) Fremgangsmåder til oprensning af messenger-RNA
DK3377059T3 (da) Hæmmere af cxcr2
DK3337902T3 (da) 3'-utr-sekvenser til stabilisering af rna
DK3292134T3 (da) Metode til dyrkning af akkermansia
DK3294885T3 (da) Fremgangsmåde til at fremstille rna
DK3394009T3 (da) Genvinding af phosphorforbindelser fra spildevand
DK3463483T3 (da) Behandling af primær ciliedyskinesi med syntetisk messenger-RNA
DK2964315T3 (da) System til behandling af neuromotorisk dysfunktion
DK3201361T3 (da) Fremgangsmåder til kvantificering af cellefrit DNA
DK3113858T3 (da) Fremgangsmåde til oprensning af il-15/il-15ralpha-baserede konjugater
DK3609529T3 (da) Rna til behandling af autoimmune sygdomme
DK3288405T3 (da) Kemisk minimeret system til tidsreduceret påsætning af øjenvippeforlængelser
DK3510042T3 (da) Fremgangsmåde til rensning af antistoffer
DK3607068T3 (da) RNA-interferensmedieret inhibering af TMPRSS6
DK3458100T3 (da) Selektiv reduktion af cystein-manipulerede antistoffer
DK3680000T3 (da) Fremgangsmåder til oprensning af antistoffer
ES2973282T3 (es) Método de purificación
DK3356386T3 (da) Fremgangsmåde til behandling af melanocortin-4 receptorbane-associerede lidelser
DK3400099T3 (da) Fremgangsmåde til methanolsyntese under anvendelse af en indiumoxidbaseret katalysator